STOCK COMPENSATION (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	May 14, 2021	Dec. 31, 2020
Common stock, shares issued	43,448,317	43,207,183	1,400,000		1,000,000
Common stock, shares authorized	600,000,000	600,000,000
Stock Compensation Plans [Member]
Common stock, shares issued	153,195
Common stock, shares authorized	634,000
Stock Bonus Plans [Member]
Common stock, shares issued	415,968
Common stock, shares authorized	783,760
Non-Qualified Stock Options Plans [Member]
Common stock, shares authorized	13,787,200
Unrecognized compensation expense	$ 18,900,000,000
Remaining compensation expense	$ 447,000
Issuance of common stock options authorized shares	2,000,000	1,800,000
Performance based stock options shares granted	250,000	72,000		1,800,000
Stock price	$ 10.48	$ 20.61
Stock options vest description	The stock options will vest 100% upon approval of the first marketing application for any pharmaceutical based upon the Company’s Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia.	The stock options will vest 100% upon the achievement of the following performance goals: (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in the US, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia
Fair value per share	$ 0.34	$ 42.00
Grant date fair value remaining outstanding		$ 63,600,000,000
Implicit life of options	1 year 3 months 18 days
Incentive Stock Option Plans [Member]
Common stock, shares authorized	138,400
Incentive Stock Bonus Plan [Member]
Common stock, shares authorized	614,500
Grant date fair value remaining outstanding	$ 8,600,000
Vested shares	463,250
Unrecognized compensation expense	$ 45,000	$ 300,000